Xenical Switch Proposal Slated For Advisory Committee Review In January
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Nonprescription Drugs and Endocrinologic & Metabolic Drugs advisory committees will meet Jan. 23 to review GSK’s application for over-the-counter use of 60 mg orlistat.
You may also be interested in...
Xenical Efficacy In "Mildly Overweight" Subjects Questioned By FDA
GlaxoSmithKline has proposed to market over-the-counter orlistat under the trade name Alli.
Avoiding GMP “Showstoppers” Keeps Manufacturers Off FDA’s “Radar”
Compliance consultants warn that certain dietary supplement good manufacturing practices violations are inspection "showstoppers" and will draw agency enforcement
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: